Analysis of Effectiveness Criteria In Pharmacoeconomic Studies of Antimicrobial Therapeutic Agents Proposed for Inclusion In The Essential Drug List (RUSSIA) In 2014-2016

Abstract

To determine the proportion of hard and surrogate endpoints chosen as effectiveness criteria in pharmacoeconomic studies of antimicrobial therapeutic agents proposed for inclusion in the essential drug lists (Russia) in 2014-2016. Analysis of pharmacoeconomic studies included in 30 antimicrobial pharmaceutical agents dossier proposed for inclusion in the essential drug list (Russia) in 2014-2016. 47 effectiveness criteria were analyzed. Hard endpoints were used in 42,5%. Two studies of antifungal agents used hard endpoints only. The proportion of hard endpoints used in research involving antibacterial agents was 53%. The least percentage of hard endpoints (26%) was used in antiviral agent research. Single study of an antiviral agent used the risk of development of resistant strains as an endpoint. 1. Hard endpoints were chosen as effectiveness criteria in pharmacoeconomic studies of antimicrobial therapeutic agents only in 42,5% of endpoints. 2. The most percentage of hard endpoints (100%) was used in antifungal agent research.3. The least percentage of hard endpoints (26%) was used in antiviral agent research. 5. Gaps in data on the possible development of antimicrobial resistance and the speed of this process do not allow to predict direct and indirect costs of prescribing individual antimicrobial therapeutic agents.